Biomarker for Rapid Diagnosis of Hemispheric Stroke

The aim of the study is to estimate the diagnostic accuracy of a combined biomarker test (including NMDA-Receptor fragments [NR2-peptide] and Glial fibrillary acidic protein) used to differentiate between cerebral ischemia and intracerebral hemorrhage in patients with acute hemispheric stroke.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Neurology, Goethe-University

Frankfurt am Main, 60590, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

hemiparesis
at least one sign of cortical involvement (e.g., aphasia, neglect, gaze deviation, reduced level of consciousness)
hospital admission within 4.5 hours after symptom onset

Exclusion criteria

stroke/TIA within the last 3 months
traumatic brain injury within the last 3 months
history of brain tumor

Treatment and study plan

Primary outcomes

Diagnostic accuracy (sensitivity and specificity for diagnosing cerebral ischemia and intracerebral hemorrhage)

Time frame: 9 months

Sponsors and collaborators

Lead sponsor

Johann Wolfgang Goethe University Hospital

Other

Registry information

Acronym: BE FAST!

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2011
First posted: Jun 10, 2009
Registry last updated: Jun 23, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed